RxDoctor Payments Data

Pablo Gomery, MD

Urology · Boston, MANPI 1477527109

Payments from drug & device makers

$114in general payments, 2019–2025

Across 2 payments — averaging $56.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$99
  • Dentsply IH AB$15

What the payments were for

  • Food & beverage$1513%
  • Education$9987%

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc1$99
Dentsply IH AB1$15

How this compares

$114 in reported general payments places this provider in the 10th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$570,950
Medicare patients
1,048
Services billed
22,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron482$334,928
MyrbetriqMirabegron171$106,376
Mirabegron ErMirabegron16$6,773
Trospium Chloride93$6,766
Silodosin67$6,497
Alfuzosin Hcl ErAlfuzosin Hcl249$6,266
Tadalafil60$4,102
Solifenacin Succinate31$2,209
Bethanechol Chloride18$2,206
Trospium Chloride ErTrospium Chloride11$1,783
Finasteride123$1,726
Methenamine Hippurate19$1,232
Trimethoprim58$874
Duloxetine Hcl19$708
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst43$694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$99$106,376171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 327 urology providers in Massachusetts.

Other urology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →